What future for cardiovascular prevention trials?
Scheen, A.J.
Revue Medicale Suisse 5(214): 1635-1636
2009
ISSN/ISBN: 1660-9379 PMID: 19772193 Document Number: 16076
Document emailed within 1 workday
Related Documents
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76Essack, Z.; Koen, J.; Slack, C.; Lindegger, G.; Newman, P.A. 2012: Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials AIDS care 24(10): 1249-1254
1995: Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration Canadian Journal of Cardiology 11(8): 649-657
1999: Canadian Cardiovascular Society 1998 Consensus Conference on the Prevention of Cardiovascular Diseases: The Role of the Cardiovascular Specialist Canadian Journal of Cardiology 15 Suppl G: 1g
Dhalla, S.; Poole, G. 2014: Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention Human Vaccines and Immunotherapeutics 10(7): 1974-1984
Makar, O.; Siabrenko, G. 2018: Influence of Physical Activity on Cardiovascular System and Prevention of Cardiovascular Diseases (Review) Georgian Medical News 2018(285): 69-74
Chopeĭ, I.V.; Rosul, M.M.; Hechko, M.M.; Chubirko, K.I.; Korabel'shchykova, M.O.; Ivan'o, N.V. 2014: Cardiovascular continuum: the role of the family doctor in prevention of cardiovascular diseases Wiadomosci Lekarskie 67(2 Pt 2): 243-247
Haire, B.; Folayan, M.Oluwatoyin.; Hankins, C.; Sugarman, J.; McCormack, S.; Ramjee, G.; Warren, M. 2013: Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP Developing World Bioethics 13(2): 87-94
Lowe, G.; Rumley, A.; Norrie, J.; Ford, I.; Shepherd, J.; Cobbe, S.; Macfarlane, P.; Packard, C. 2000: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thrombosis and Haemostasis 84(4): 553-558
Goin, D.E.; Pearson, R.M.; Craske, M.G.; Stein, A.; Pettifor, A.; Lippman, S.A.; Kahn, K.; Neilands, T.B.; Hamilton, E.L.; Selin, A.; MacPhail, C.; Wagner, R.G.; Gomez-Olive, F.Xavier.; Twine, R.; Hughes, J.P.; Agyei, Y.; Laeyendecker, O.; Tollman, S.; Ahern, J. 2020: Depression and Incident HIV in Adolescent Girls and Young Women in HIV Prevention Trials Network 068: Targets for Prevention and Mediating Factors American Journal of Epidemiology 189(5): 422-432
Huo, Y.; Li, X.Y. 2018: Deepen our thoughts on the prevention of cardiovascular disease and actively contribute to the earlier appearance of the turning point noting the reduced prevalence of cardiovascular diseases Zhonghua Xin Xue Guan Bing Za Zhi 46(1): 3-6
Rumboldt, Z. 2007: Lessons learned from large cardiovascular trials Medicinski Arhiv 61(2 Suppl. 1): 38-40
Joule, N. 1998: 50 years of clinical trials: past, present and future Bulletin of medical ethics No. 142: 22-24
Breckenkamp, J.; Laaser, U.; Meyer, S. 1995: The German Cardiovascular Prevention Study: social gradient for the net effects in prevention of hypercholesterolemia Zeitschrift für Kardiologie 84(9): 694-699
Wand, H.; Ramjee, G. 2013: High prevalence of obesity among women who enrolled in HIV prevention trials in KwaZulu-Natal, South Africa: healthy diet and life style messages should be integrated into HIV prevention programs Bmc Public Health 13: 159
Wand, H.; Ramjee, G. 2013: High prevalence of obesity among women who enrolled in HIV prevention trials in KwaZulu-Natal, South Africa: healthy diet and life style messages should be integrated into HIV prevention programs Bmc Public Health 13: 159
Kleinert, S. 1999: HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation Lancet 354(9181): 841
Esparza, Jé.; Osmanov, S.; Pattou-Markovic, C.; Touré, C.; Chang, M.Louise.; Nixon, S. 2002: Past, present and future of HIV vaccine trials in developing countries Vaccine 20(15): 1897-1898
Pickering, T.G. 1997: Lessons from the Trials of Hypertension Prevention, phase II. Energy intake is more important than dietary sodium in the prevention of hypertension Archives of Internal Medicine 157(6): 596-597
Boissel, J.P. 1984: Impact of randomized controlled trials on the progress of therapy in cardiovascular diseases Revue d'Epidemiologie et de Sante Publique 32(3-4): 212-218